Beyond migraine: CGRP inhibition at the neurovascular interface and its implications for glaucoma risk

doi:10.1080/17512433.2026.2716922

August 10, 2026Expert Review of Clinical Pharmacology

Beyond migraine: CGRP inhibition at the neurovascular interface and its implications for glaucoma risk

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to explore the connection between migraine, CGRP inhibition, and glaucoma risk.
Reviewed epidemiologic studies linking migraine and glaucoma.
Examined the role of CGRP in neurovascular functions.
Analyzed potential implications for therapeutic interventions.
Individuals with migraine are at a higher risk for developing glaucoma.
CGRP inhibition may play a significant role at the neurovascular interface.
Findings indicate potential benefits of CGRP targeting in reducing glaucoma risk among migraine sufferers.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Epidemiologic studies show migraine influences glaucoma risk in individuals with neurological conditions, suggesting new therapeutic avenues.

Abstract

Migraine and glaucoma are prevalent conditions associated with significant neurological and visual morbidity. Epidemiologic studies have repeatedly suggested that individuals with migraine may c...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a7d75e62b0e0cff3f63ee56 https://doi.org/10.1080/17512433.2026.2716922

View at Publisher

Ask AI

Bookmark

Share

Beyond migraine: CGRP inhibition at the neurovascular interface and its implications for glaucoma risk

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Beyond migraine: CGRP inhibition at the neurovascular interface and its implications for glaucoma risk

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading